In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.


Journal

Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 28 12 2020
accepted: 08 02 2021
revised: 27 01 2021
pubmed: 21 2 2021
medline: 22 6 2021
entrez: 20 2 2021
Statut: ppublish

Résumé

The idea of treating COVID-19 with statins is biologically plausible, although it is still controversial. The systematic review and meta-analysis aimed to address the association between the use of statins and risk of mortality in patients with COVID-19. Several electronic databases, including PubMed, SCOPUS, EuropePMC, and the Cochrane Central Register of Controlled Trials, with relevant keywords up to 11 November 2020, were used to perform a systematic literature search. This study included research papers containing samples of adult COVID-19 patients who had data on statin use and recorded mortality as their outcome of interest. Risk estimates of mortality in statin users versus non-statin users were pooled across studies using inverse-variance weighted DerSimonian-Laird random-effect models. Thirteen studies with a total of 52,122 patients were included in the final qualitative and quantitative analysis. Eight studies reported in-hospital use of statins; meanwhile, the remaining studies reported pre-admission use of statins. In-hospital use of statin was associated with a reduced risk of mortality (RR 0.54, 95% CI 0.50-0.58, p < 0.00001; I This meta-analysis showed that in-hospital use of statins was associated with a reduced risk of mortality in patients with COVID-19.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The idea of treating COVID-19 with statins is biologically plausible, although it is still controversial. The systematic review and meta-analysis aimed to address the association between the use of statins and risk of mortality in patients with COVID-19.
METHODS METHODS
Several electronic databases, including PubMed, SCOPUS, EuropePMC, and the Cochrane Central Register of Controlled Trials, with relevant keywords up to 11 November 2020, were used to perform a systematic literature search. This study included research papers containing samples of adult COVID-19 patients who had data on statin use and recorded mortality as their outcome of interest. Risk estimates of mortality in statin users versus non-statin users were pooled across studies using inverse-variance weighted DerSimonian-Laird random-effect models.
RESULTS RESULTS
Thirteen studies with a total of 52,122 patients were included in the final qualitative and quantitative analysis. Eight studies reported in-hospital use of statins; meanwhile, the remaining studies reported pre-admission use of statins. In-hospital use of statin was associated with a reduced risk of mortality (RR 0.54, 95% CI 0.50-0.58, p < 0.00001; I
CONCLUSION CONCLUSIONS
This meta-analysis showed that in-hospital use of statins was associated with a reduced risk of mortality in patients with COVID-19.

Identifiants

pubmed: 33608850
doi: 10.1007/s43440-021-00233-3
pii: 10.1007/s43440-021-00233-3
pmc: PMC7895740
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

769-780

Références

Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1241-1242
pubmed: 32683322
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2
pubmed: 32674818
Ann Transl Med. 2016 Nov;4(21):421
pubmed: 27942512
J Am Heart Assoc. 2020 Dec 15;9(24):e018475
pubmed: 33092446
Lancet Respir Med. 2021 Mar;9(3):275-284
pubmed: 33422263
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Can J Kidney Health Dis. 2020 Jul 7;7:2054358120938573
pubmed: 32685180
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1613-1615
pubmed: 32882643
Inflamm Regen. 2020 Oct 1;40:37
pubmed: 33014208
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
Intern Emerg Med. 2020 Nov;15(8):1573-1576
pubmed: 33011928
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):258-259
pubmed: 32347925
Am J Cardiol. 2020 Nov 1;134:153-155
pubmed: 32891399
J Health Econ Outcomes Res. 2020 Sep 29;7(2):165-174
pubmed: 33043063
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):157-164
pubmed: 33135047
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124
pubmed: 32387623
Crit Care. 2020 Jul 14;24(1):429
pubmed: 32664990
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
J Infect Dis. 2012 Jan 1;205(1):13-9
pubmed: 22170954
Arch Med Sci. 2020 Apr 25;16(3):490-496
pubmed: 32399094
Clin Rev Allergy Immunol. 2021 Apr;60(2):175-199
pubmed: 32378144
Atherosclerosis. 2012 Dec;225(2):381-7
pubmed: 23062767
Clin Med (Lond). 2017 Oct;17(5):403-407
pubmed: 28974587
Antiviral Res. 2013 Sep;99(3):417-35
pubmed: 23831494
Open Forum Infect Dis. 2015 Mar 20;2(1):ofv028
pubmed: 26034777
Int J Infect Dis. 2020 Jul;96:615-617
pubmed: 32502659
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Atherosclerosis. 2015 Aug;241(2):433-42
pubmed: 26074317
Ther Apher Dial. 2021 Oct;25(5):706-709
pubmed: 33040468
mBio. 2020 Mar 20;11(2):
pubmed: 32198163
Expert Rev Respir Med. 2020 Nov;14(11):1149-1163
pubmed: 32734777
Pharmacol Res. 2020 Jun;156:104803
pubmed: 32289478
J Clin Med. 2020 Jun 18;9(6):
pubmed: 32570882
Diabetes Metab. 2021 Mar;47(2):101202
pubmed: 33091555
Thromb Haemost. 2016 Mar;115(3):520-32
pubmed: 26632869
Biochem Pharmacol. 2015 Feb 1;93(3):343-51
pubmed: 25482567
EClinicalMedicine. 2020 Dec;29:100639
pubmed: 33251499
J Clin Anesth. 2020 Dec;67:110005
pubmed: 32707517
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
Signal Transduct Target Ther. 2020 Dec 4;5(1):283
pubmed: 33277466
Clin Med Insights Circ Respir Pulm Med. 2020 Sep 17;14:1179548420959165
pubmed: 32994700
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Pathogens. 2020 Sep 17;9(9):
pubmed: 32957539
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620960797
pubmed: 33079569
Intensive Care Med. 2020 Aug;46(8):1603-1606
pubmed: 32415314
Thromb Res. 2020 Oct;194:101-115
pubmed: 32788101
Am J Cardiol. 2020 Dec 1;136:149-155
pubmed: 32946859
Pediatr Crit Care Med. 2013 Nov;14(9):e438-41
pubmed: 24226567
Am J Emerg Med. 2021 Aug;46:204-211
pubmed: 33071085

Auteurs

Hikmat Permana (H)

Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia. hikmat.permana@unpad.ac.id.

Ian Huang (I)

Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Aga Purwiga (A)

Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Nuraini Yasmin Kusumawardhani (NY)

Division of Cardiology and Vascular Medicine, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Teddy Arnold Sihite (TA)

Division of Cardiology and Vascular Medicine, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Erwan Martanto (E)

Division of Cardiology and Vascular Medicine, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Rudi Wisaksana (R)

Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Nanny Natalia M Soetedjo (NNM)

Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH